Spanish pacemaker registry. 21st official report of Heart Rhythm Association of the Spanish Society of Cardiology (2023)

IF 7.2 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Revista española de cardiología (English ed.) Pub Date : 2024-09-07 DOI:10.1016/j.rec.2024.07.012
Manuel Molina-Lerma , Rocío Cózar-León , Francisco Javier García-Fernández , David Calvo
{"title":"Spanish pacemaker registry. 21st official report of Heart Rhythm Association of the Spanish Society of Cardiology (2023)","authors":"Manuel Molina-Lerma ,&nbsp;Rocío Cózar-León ,&nbsp;Francisco Javier García-Fernández ,&nbsp;David Calvo","doi":"10.1016/j.rec.2024.07.012","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Data on implants of cardiac pacing systems in Spain in 2023 are presented.</div></div><div><h3>Methods</h3><div>The registry is based on the information provided by centers to the recording platform of the Heart Rhythm Association after device implantations, through Cardiodispositivos, the online platform of the National Registry. Other information sources include: <em>a)</em> data transfers from the manufacturing and marketing industry; <em>b)</em> the European pacemaker patient card; and <em>c)</em> local databases submitted by the implanting centers.</div></div><div><h3>Results</h3><div>In 2023, 112 hospitals participated in the registry (30 more than in 2022). A total of 24 343 device implantations were reported (48.1% more than in 2022) compared with 45 120 reported by Eucomed (European Confederation of Medical Suppliers Associations). Of these, 1646 were cardiac resynchronization therapy pacemakers. The devices showing the largest increases were leadless pacemakers, with 963 devices implanted, representing an 18.1% increase over 2022. The most frequent indication was atrioventricular block followed, for the first time, by atrial tachyarrhythmia with slow ventricular response. The number of devices included in remote monitoring also increased (cardiac resynchronization therapy defibrillators, 71%; cardiac resynchronization therapy pacemakers, 63%; and conventional pacemakers, 28%), although more moderately.</div></div><div><h3>Conclusions</h3><div>In 2023, there was an increase in the number of institutions participating in the registry. The reporting of device implantations rose by 48.1%, and the implantation of leadless pacemakers grew by 18.1%. Remote monitoring also experienced modest growth compared with previous years.</div></div>","PeriodicalId":38430,"journal":{"name":"Revista española de cardiología (English ed.)","volume":"77 11","pages":"Pages 947-956"},"PeriodicalIF":7.2000,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista española de cardiología (English ed.)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1885585724002676","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Data on implants of cardiac pacing systems in Spain in 2023 are presented.

Methods

The registry is based on the information provided by centers to the recording platform of the Heart Rhythm Association after device implantations, through Cardiodispositivos, the online platform of the National Registry. Other information sources include: a) data transfers from the manufacturing and marketing industry; b) the European pacemaker patient card; and c) local databases submitted by the implanting centers.

Results

In 2023, 112 hospitals participated in the registry (30 more than in 2022). A total of 24 343 device implantations were reported (48.1% more than in 2022) compared with 45 120 reported by Eucomed (European Confederation of Medical Suppliers Associations). Of these, 1646 were cardiac resynchronization therapy pacemakers. The devices showing the largest increases were leadless pacemakers, with 963 devices implanted, representing an 18.1% increase over 2022. The most frequent indication was atrioventricular block followed, for the first time, by atrial tachyarrhythmia with slow ventricular response. The number of devices included in remote monitoring also increased (cardiac resynchronization therapy defibrillators, 71%; cardiac resynchronization therapy pacemakers, 63%; and conventional pacemakers, 28%), although more moderately.

Conclusions

In 2023, there was an increase in the number of institutions participating in the registry. The reporting of device implantations rose by 48.1%, and the implantation of leadless pacemakers grew by 18.1%. Remote monitoring also experienced modest growth compared with previous years.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
西班牙起搏器登记。西班牙心脏病学会心律协会第 21 次正式报告(2023 年)。
介绍:介绍了 2023 年西班牙心脏起搏系统的植入数据:该登记簿基于各中心通过国家登记簿在线平台 Cardiodispositivos 向心脏节律协会记录平台提供的设备植入后的信息。其他信息来源包括:a)制造和营销行业的数据传输;b)欧洲起搏器患者卡;c)植入中心提交的本地数据库:2023 年,112 家医院参与了登记(比 2022 年增加了 30 家)。共报告了 24 343 例设备植入(比 2022 年增加 48.1%),而欧洲医疗供应商协会联合会(Eucomed)报告的植入数量为 45 120 例。其中,1646 台为心脏再同步治疗起搏器。增幅最大的设备是无引线起搏器,共植入 963 台,比 2022 年增长了 18.1%。最常见的适应症是房室传导阻滞,其次是伴有缓慢心室反应的房性快速性心律失常,这还是第一次。纳入远程监测的设备数量也有所增加(心脏再同步治疗除颤器,71%;心脏再同步治疗起搏器,63%;传统起搏器,28%),但增幅不大:2023 年,参与登记的机构数量有所增加。设备植入报告增加了 48.1%,无引线起搏器植入增加了 18.1%。与前几年相比,远程监护也有小幅增长。英文全文见:www.revespcardiol.org/en。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.70
自引率
0.00%
发文量
219
期刊最新文献
Incidence and chronology of atrioventricular block and outcomes after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Interaction between age and therapeutic approach on outcome in older patients with patent foramen ovale-associated stroke. Catheter-directed interventions in acute pulmonary embolism. Position statement of SEC-Interventional Cardiology Association/SEC-Ischemic Heart Disease and Acute Cardiovascular Care Association/SEC-GT Pulmonary Hypertension Working Group. Outcomes after percutaneous coronary intervention or bypass surgery for ischemic cardiomyopathy. Cardioverter-defibrillator implantation in chronic Chagas cardiomyopathy: the Rassi death risk score for decision-making.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1